Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

selonsertib

- PMLiVE

CymaBay Therapeutics plummets after abandoning NASH drug

Failure of mid-stage liver disease candidate caused shares to slip over 75%

Novartis day

Novartis makes case for NASH candidate tropifexor

Race to market intensifies as rivals strive to win first-in-class

- PMLiVE

Boehringer bolsters NASH pipeline with $870m Yuhan deal

Strengthens existing relationship

- PMLiVE

Genfit presses the gas on NASH with combo trials

Latest move in tight race for NASH prize

- PMLiVE

Gilead’s NASH drug fails again

Drug failed to match results from placebo group

- PMLiVE

Genfit claims FDA breakthrough status for liver disease drug

Elafibranor up for speedy US review

- PMLiVE

Gilead drives NASH development with insitro collaboration

Announcement comes days after Novo Nordisk deal

- PMLiVE

Promethera’s liver failure stem cell therapy clears first hurdle

Technique could be alternative to transplant

- PMLiVE

Intercept builds its case for Ocaliva in NASH, but safety still an issue

Mixed efficacy and safety results hits NASH frontrunner

- PMLiVE

Alnylam swaps Sanofi for Regeneron as R&D partner

Novel alliance between two biotechs

- PMLiVE

Intercept NASH drug closes in on FDA approval

Although the drug failed to meet secondary endpoint

- PMLiVE

Gilead lead NASH drug flunks phase 3 test

Analysts suspect the setback could prompt Gilead to license other candidates

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links